Cytokinetics is facing pressure to sell itself to a large pharma company after positive late-stage results of its heart drug, but CEO Robert Blum believes the biotech can launch the treatment on its own. The drug, aficamten, showed promising results in treating obstructive hypertrophic cardiomyopathy and investors speculated the company would get acquired. Despite doubts about the company’s resources and ability to compete with larger pharma companies, Blum remains focused on building a commercial business. While open to discussing potential acquisitions, Cytokinetics is moving forward with its original plan to launch the medication independently.
Source link
Cytokinetics CEO stresses company can launch heart drug on its own
